On Thursday, Shares of Bank of America Corporation (NYSE:BAC), lost -1.46% to $18.18.
Bank of America Corporation declared the Board of Directors declared a regular quarterly cash dividend on Bank of America common stock of $0.05 per share, payable September 25 to shareholders of record as of September 4.
The board also declared a regular quarterly cash dividend of $1.75 per share on the 7 percent Cumulative Redeemable Preferred Stock, Series B. The dividend is payable October 23 to shareholders of record as of October 9.
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -1.63% to $68.24, during its last trading session.
Bristol-Myers Squibb Company, stated results for the second quarter of 2015, which were highlighted by strong global sales, key regulatory and clinical advances for Opdivo and noteworthy clinical data on the company’s Immuno-Oncology portfolio presented at the American Society of Clinical Oncology (ASCO).
SECOND QUARTER FINANCIAL RESULTS
- Bristol-Myers Squibb posted second quarter 2015 revenues of $4.2 billion, an enhance of 7% contrast to the same period a year ago. Global revenues raised 16% adjusted for foreign exchange impact.
- S. revenues reduced 3% to $1.8 billion in the quarter contrast to the same period a year ago. International revenues raised 17%.
- Gross margin as a percentage of revenues was 75.7% in the quarter contrast to 74.5% in the same period a year ago.
- Marketing, selling and administrative expenses raised 2% to $968 million in the quarter.
- Advertising and product promotion spending reduced 11% to $167 million in the quarter.
- Research and development expenses raised 31% to $1.9 billion in the quarter, primarily due to the acquisition of Flexus Biosciences, Inc.
- The effective tax rate was 311.5% in the quarter, contrast to 25.4% in the second quarter last year.
- The company stated net loss attributable to Bristol-Myers Squibb of $130 million, or $0.08 per share, in the quarter contrast to net earnings of $333 million, or $0.20 per share, a year ago. The results in the current quarter comprise an $800 million R&D charge ($0.48 per share) resulting from the Flexus acquisition, which was not deductible for tax purposes.
- The company stated non-GAAP net earnings attributable to Bristol-Myers Squibb of $890 million, or $0.53 per share, in the second quarter, contrast to $798 million, or $0.48 per share, for the same period in 2014. An overview of specified items is talk abouted under the “Use of Non-GAAP Financial Information” section.
- Cash, cash equivalents and marketable securities were $10.1 billion, with a net cash position of $2.7 billion, as of June 30, 2015.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Cloud Peak Energy Inc. (NYSE:CLD), ended its last trade with -9.34% loss, and closed at $3.01, hitting its lowest level.
Cloud Peak Energy, declared second quarter 2015 shipments and updated its annual Adjusted EBITDA guidance. Results for the second quarter and first six months of 2015 are predictable to be declared on July 29, 2015.
Second quarter 2015 shipments from the Company’s three mines were 16.0 million tons contrast to 20.6 million tons in the second quarter of 2014. For the full year 2015, the Company now anticipates shipments to be between 74 and 78 million tons.
Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The company operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.